TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane CAS Number: 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

Lab: BAT

F1_M3

C Number: C99028

Lock Date: 09/20/2005

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMSE Version: 2.0.0

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|--|----------|-----------|------------|------------------|
| Disposition Summary | | | | |
| Animals Initially in Study Early Deaths | 50 | 50 | 50 | 50 |
| Moribund Sacrifice | 7 | 4 | 2 | 8 |
| Natural Death | 6 | 6 | 6 | 14 |
| Survivors | ū | · · | · · | • • |
| Moribund Sacrifice | | 1 | | |
| Natural Death | | 1 | | 1 |
| Terminal Sacrifice | 37 | 38 | 42 | 27 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |
| ALIMENTARY SYSTEM | | | | |
| Esophagus | (50) | (50) | (50) | (50) |
| Inflammation | , , | ` ' | 1 (2%) | 1 (2%) |
| Ulcer | | | 1 (2%) | , , |
| Gallbladder | (50) | (49) | (49) | (50) |
| Inflammation | | | | 1 (2%) |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Epithelium, Necrosis | 1 (2%) | (==) | (=0) | (=0) |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Inflammation | | | | 1 (2%) |
| Mineralization | | | | 1 (2%) 1 (2%) |
| Epithelium, Diverticulum Peyer's Patch, Hyperplasia | 1 (2%) | | 1 (2%) | 1 (2%) |
| Serosa, Inflammation | 1 (270) | | I (∠70) | 1 (2%) |
| Liver | (50) | (50) | (50) | (50) |
| Angiectasis | (30) | 1 (2%) | (30) | (30) |
| Basophilic Focus | 3 (6%) | 1 (2%) | 1 (2%) | 3 (6%) |
| Clear Cell Focus | 26 (52%) | 29 (58%) | 34 (68%) | 16 (32%) |
| Congestion | (0_70) | 25 (5575) | 3 . (0070) | 1 (2%) |
| Eosinophilic Focus | 26 (52%) | 28 (56%) | 27 (54%) | 27 (54%) |
| Fibrosis | (0_/0) | == (0070) | 1 (2%) | =: (0:/0) |
| Hemorrhage | | | (/ | 1 (2%) |
| Infarct | 1 (2%) | 2 (4%) | | 2 (4%) |
| Inflammation | 5 (Ì0%́) | 3 (6%) | 5 (10%) | 5 (Ì0%́) |
| Mixed Cell Focus | 9 (18%) | 9 (18%) | 9 (18%) | 7 (14%) |
| Regeneration | , , | • | , , | 1 (2%) |
| Tension Lipidosis | 9 (18%) | 1 (2%) | 3 (6%) | 6 (12%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG | |
|--|-----------|------------|-----------|-----------|--|
| Thrombosis | | | 2 (4%) | 1 (2%) | |
| Bile Duct, Cyst | | | , | 1 (2%) | |
| Centrilobular, Degeneration | | | | 3 (6%) | |
| Hepatocyte, Hypertrophy | | 1 (2%) | | 1 (2%) | |
| Hepatocyte, Necrosis | 3 (6%) | 2 (4%) | 10 (20%) | 2 (4%) | |
| Hepatocyte, Vacuolization Cytoplasmic, | 14 (28%) | 11 (22%) | 12 (24%) | 13 (26%) | |
| Diffuse | 14 (2070) | 11 (2270) | 12 (2470) | 10 (2070) | |
| Oval Cell, Hyperplasia | | | 2 (4%) | | |
| Serosa, Inflammation | | 1 (2%) | 2 (4 /8) | | |
| | (5) | 1 (2%) | (4.4) | (1) | |
| Mesentery | (5) | (8) | (11) | (1) | |
| Inflammation | 4 (000() | 7 (000() | 3 (27%) | 1 (100%) | |
| Necrosis | 4 (80%) | 7 (88%) | 7 (64%) | (50) | |
| Pancreas | (50) | (50) | (50) | (50) | |
| Basophilic Focus | 1 (2%) | | | 1 (2%) | |
| Acinus, Atrophy | 1 (2%) | | 1 (2%) | 1 (2%) | |
| Acinus, Hyperplasia | 8 (16%) | 4 (8%) | 13 (26%) | 2 (4%) | |
| Artery, Inflammation | | 1 (2%) | | | |
| Duct, Cyst | | 2 (4%) | 2 (4%) | 2 (4%) | |
| Salivary Glands | (50) | (50) | (50) | (50) | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) | |
| Edema | | | | 1 (2%) | |
| Erosion | | 1 (2%) | | 1 (2%) | |
| Inflammation | 1 (2%) | 3 (6%) | | 2 (4%) | |
| Ulcer | 1 (2%) | 1 (2%) | 1 (2%) | 7 (14%) | |
| Epithelium, Hyperplasia | (=75) | 3 (6%) | 1 (2%) | 2 (4%) | |
| Stomach, Glandular | (50) | (50) | (50) | (50) | |
| Erosion | (00) | (00) | (00) | 4 (8%) | |
| Inflammation | | | 1 (2%) | 1 (2%) | |
| Glands, Hyperplasia | | | 1 (2%) | 1 (270) | |
| Serosa, Inflammation | | | 1 (2%) | | |
| | (1) | (0) | | (0) | |
| Tongue Mineralization | 1 (100%) | (0) | (0) | (0) | |
| | 1 (100%) | (F) | (4) | (4) | |
| Tooth | (5) | (5) | (4) | (1) | |
| Dysplasia | 4 (80%) | 4 (80%) | 4 (050() | 1 (100%) | |
| Inflammation | | ((000) | 1 (25%) | . (| |
| Peridontal Tissue, Fibrosis | | 1 (20%) | 2 (50%) | 1 (100%) | |
| RDIOVASCULAR SYSTEM | | | | | |
| Blood Vessel | (50) | (50) | (50) | (50) | |
| Adventitia, Inflammation | | | 2 (4%) | | |
| Heart | (50) | (50) | (50) | (50) | |
| Artery, Inflammation | 2 (4%) | \ · - / | 2 (4%) | ` ' | |
| Atrium, Thrombosis | (, | | (, | 1 (2%) | |
| Epicardium, Hyperplasia | | | 1 (2%) | · \- · -/ | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: SKIN APPLICATION Species/Strain: MICE/B6C3F1

TDMS No. 99028 - 06

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG | |
|---|----------|-----------|-----------|-----------|--|
| | | | | | |
| Epicardium, Inflammation | 1 (2%) | | 1 (2%) | | |
| Myocardium, Cardiomyopathy | 10 (20%) | 12 (24%) | 7 (14%) | 28 (56%) | |
| Myocardium, Fibrosis | | 3 (6%) | 3 (6%) | 13 (26%) | |
| Myocardium, Infiltration Cellular, Mononuclear Cell | 11 (22%) | 12 (24%) | 8 (16%) | 28 (56%) | |
| Myocardium, Mineralization | | 1 (2%) | 2 (4%) | 3 (6%) | |
| Myocardium, Necrosis | 3 (6%) | 2 (4%) | | 1 (2%) | |
| Myocardium, Vacuolization Cytoplasmic | 10 (20%) | 15 (30%) | 11 (22%) | 29 (58%) | |
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (49) | (50) | (50) | (50) | |
| Degeneration | 1 (2%) | | | - 41-11 | |
| Hyperplasia | 13 (27%) | 4 (8%) | 11 (22%) | 2 (4%) | |
| Hypertrophy | 24 (49%) | 34 (68%) | 26 (52%) | 22 (44%) | |
| Subcapsular, Hyperplasia | 43 (88%) | 44 (88%) | 51 (102%) | 39 (78%) | |
| Adrenal Medulla | (49) | (50) | (50) | (50) | |
| Hyperplasia | | 2 (4%) | 1 (2%) | | |
| Pigmentation, Melanin | | | | 1 (2%) | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) | |
| Hyperplasia | 32 (64%) | 35 (70%) | 39 (78%) | 21 (42%) | |
| Parathyroid Gland | (47) | (33) | (45) | (46) | |
| Cyst | 1 (2%) | | | 2 (4%) | |
| Pituitary Gland | (50) | (49) | (49) | (49) | |
| Pars Distalis, Cyst | 6 (12%) | 1 (2%) | 3 (6%) | 3 (6%) | |
| Pars Distalis, Hyperplasia | 20 (40%) | 5 (10%) | 17 (35%) | 5 (10%) | |
| Pars Intermedia, Cyst | 1 (2%) | | | | |
| Thyroid Gland | (50) | (50) | (50) | (50) | |
| Inflammation | 1 (2%) | | | | |
| Follicle, Cyst | | | 2 (4%) | | |
| Follicular Cell, Hyperplasia | | | | 2 (4%) | |
| GENERAL BODY SYSTEM | | | | | |
| None | | | | | |
| GENITAL SYSTEM | | | | | |
| Epididymis | (50) | (50) | (50) | (50) | |
| Atrophy | 1 (2%) | (33) | (30) | (/ | |
| Granuloma Sperm | . (= /0) | 1 (2%) | 2 (4%) | | |
| Inflammation | 4 (8%) | . (=/5) | 1 (2%) | 4 (8%) | |
| Preputial Gland | (50) | (50) | (50) | (50) | |
| -1 | (-0) | (55) | (30) | (/ | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane CAS Number: 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG | |
|--|----------|-----------|-----------|-----------|--|
| Fibrosis | | | 1 (2%) | | |
| Inflammation | 2 (4%) | 3 (6%) | 2 (4%) | 1 (2%) | |
| Duct, Ectasia | 3 (6%) | 4 (8%) | 2 (170) | 1 (2%) | |
| Prostate | (50) | (50) | (50) | (50) | |
| Atrophy | 1 (2%) | (00) | (00) | (00) | |
| Inflammation | 1 (2%) | | 2 (4%) | 3 (6%) | |
| Epithelium, Hyperplasia | 16 (32%) | 4 (8%) | 3 (6%) | 6 (12%) | |
| Seminal Vesicle | (50) | (50) | (50) | (50) | |
| Atrophy | 1 (2%) | (, | () | () | |
| Dilatation | (/ | | 1 (2%) | | |
| Testes | (50) | (50) | (50) | (50) | |
| Mineralization | 1 (2%) | 1 (2%) | () | () | |
| Germinal Epithelium, Degeneration | 11 (22%) | 7 (14%) | 6 (12%) | 9 (18%) | |
| Interstitial Cell, Hyperplasia | 1 (2%) | , , | , | , | |
| EMATOPOIETIC SYSTEM | | | | | |
| Bone Marrow | (50) | (50) | (50) | (50) | |
| Angiectasis | | 1 (2%) | | | |
| Atrophy | 1 (2%) | | | | |
| Hemorrhage | 1 (2%) | | | 2 (4%) | |
| Myelofibrosis | | | 1 (2%) | | |
| Lymph Node | (2) | (1) | (2) | (1) | |
| Lymph Node, Mandibular | (50) | (50) | (50) | (50) | |
| Hyperplasia, Plasma Cell | 1 (2%) | 1 (2%) | | 2 (4%) | |
| Lymph Node, Mesenteric | (50) | (50) | (50) | (49) | |
| Hemorrhage | 1 (2%) | | | 2 (4%) | |
| Hyperplasia, Lymphoid | | | 1 (2%) | | |
| Hyperplasia, Plasma Cell | | 1 (2%) | | | |
| Spleen | (50) | (50) | (50) | (50) | |
| Atrophy | 3 (6%) | 1 (2%) | 1 (2%) | 1 (2%) | |
| Hematopoietic Cell Proliferation | | | 1 (2%) | 1 (2%) | |
| Thymus | (49) | (49) | (47) | (49) | |
| Inflammation | | | 1 (2%) | | |
| ITEGUMENTARY SYSTEM | | | | | |
| Mammary Gland | (1) | (0) | (0) | (0) | |
| Duct, Dilatation | 1 (100%) | | | () | |
| Skin | (50) | (50) | (50) | (50) | |
| Ulcer | 1 (2%) | 1 (2%) | | 1 (2%) | |
| Site Of Application - Dermis, Fibrosis | 6 (12%) | 1 (2%) | 2 (4%) | 25 (50%) | |
| Site Of Application - Dermis, Inflammation | 3 (6%) | 1 (2%) | 3 (6%) | 13 (26%) | |
| Site Of Application - Epidermis, Hyperplasia | 8 (16%) | 1 (2%) | 4 (8%) | 28 (56%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane CAS Number: 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG | |
|---|--------------------------|----------------------------|------------------|------------------|--|
| Site Of Application - Epidermis, Ulcer Subcutaneous Tissue, Edema | 3 (6%) | 1 (2%) | 1 (2%) | 4 (8%) 1 (2%) | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone Cartilage, Femur Joint, Hyperplasia Femur, Joint, Inflammation | (50) 1 (2%) 1 (2%) | (50) | (50) | (50) | |
| Skeletal Muscle | (0) | (0) | (0) | (1) | |
| NERVOUS SYSTEM | | | | | |
| Brain Ventricle, Inflammation | (50) 1 (2%) | (50) | (50) | (50) | |
| RESPIRATORY SYSTEM | | | | | |
| Lung Inflammation | (50) 3 (6%) | (50) 3 (6%) | (50) | (50) | |
| Thrombosis Alveolar Epithelium, Hyperplasia Alveolus, Infiltration Cellular, Histiocyte | 2 (4%) 3 (6%) | 1 (2%) 1 (2%) 1 (2%) | 1 (2%) 3 (6%) | 2 (4%) | |
| Mediastinum, Inflammation Perivascular, Cyst Serosa, Hyperplasia | | 1 (2%) 1 (2%) 1 (2%) | | | |
| Nose Inflammation | (50) 8 (16%) | (50) 3 (6%) | (50) 2 (4%) | (50) 3 (6%) | |
| Respiratory Epithelium, Hyperplasia | 1 (2%) | | 1 (2%) | | |
| SPECIAL SENSES SYSTEM Eye | (50) | (50) | (50) | (50) | |
| Arteriole, Inflammation Cornea, Hyperplasia | 1 (2%) | (30) | (30) | 1 (2%) | |
| Cornea, Inflammation Retrobulbar, Inflammation Harderian Gland | 3 (6%) 1 (2%) (50) | (50) | (50) | (49) | |
| Cyst Hemorrhage | 1 (2%) | (30) | (30) | (49) 1 (2%) | |
| Epithelium, Hyperplasia Zymbal's Gland | (1) | (0) | 2 (4%) (0) | (1) | |
| Cyst | 1 (100%) | | | 1 (100%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG | |
|--|--|---|--|--------------------------------|--|
| Inflammation | 1 (100%) | | | | |
| JRINARY SYSTEM | | | | | |
| Kidney Cyst Hydronephrosis Infarct Infiltration Cellular, Mononuclear Cell | (50) 7 (14%) 5 (10%) | (50) 8 (16%) 1 (2%) 1 (2%) 3 (6%) | (50) 11 (22%) 3 (6%) 1 (2%) | (50) 11 (22%) 1 (2%) | |
| Inflammation Mineralization Nephropathy Artery, Inflammation | 4 (8%) 22 (44%) 45 (90%) 2 (4%) | 2 (4%) 26 (52%) 42 (84%) | 4 (8%) 21 (42%) 44 (88%) 2 (4%) | 1 (2%) 25 (50%) 37 (74%) | |
| Urinary Bladder Mineralization | (50) 1 (2%) | (50) | (50) | (50) | |

*** END OF MALE ***

TDMS No. 99028 - 06 Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

TDMS No. 99028 - 06

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|--|-----------|------------------|----------------------|-----------|
| Disposition Summary | | | | |
| Animals Initially in Study | 50 | 50 | 50 | 50 |
| Early Deaths | 44 | F | 7 | 4.4 |
| Moribund Sacrifice Natural Death | 11 8 | 5 7 | 7 6 | 11 2 |
| Survivors | 8 | , | O | 2 |
| Natural Death | | | | 1 |
| Terminal Sacrifice | 31 | 38 | 37 | 36 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |
| ALIMENTARY SYSTEM | | | | |
| Esophagus | (50) | (50) | (50) | (50) |
| Inflammation | | | 1 (2%) | |
| Gallbladder | (50) | (50) | (50) | (50) |
| Fibrosis | 1 (2%) | | | 1 (29/) |
| Epithelium, Cyst Epithelium, Hyperplasia | 1 (2%) | | | 1 (2%) |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation | (55) | 1 (2%) | (30) | (00) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation | | 1 (2%) | | |
| Epithelium, Diverticulum | 1 (2%) | () | () | 4 |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation Intestine Small, Ileum | (50) | 1 (2%) | (EO) | (50) |
| Inflammation | (50) | (50) 1 (2%) | (50) 1 (2%) | (50) |
| Ulcer | | 1 (2%) | 1 (2/0) | |
| Epithelium, Diverticulum | | 1 (2%) | | |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Epithelium, Hyperplasia | | . , | , , | 1 (2%) |
| Peyer's Patch, Diverticulum | 1 (2%) | | | |
| Peyer's Patch, Hyperplasia | (50) | 2 (4%) | (50) | 1 (2%) |
| Liver | (50) | (50) | (50) | (50) |
| Angiectasis Basophilic Focus | 1 (2%) | 2 (4%) | 2 (4%) 2 (4%) | 2 (4%) |
| Clear Cell Focus | 1 (2%) | 2 (4%) 3 (6%) | ∠ (4 70) | 5 (10%) |
| Eosinophilic Focus | 12 (24%) | 9 (18%) | 11 (22%) | 12 (24%) |
| Hematopoietic Cell Proliferation | (= . , 5) | 0 (.0,0) | (== / =/ | 1 (2%) |
| Infarct | 1 (2%) | | | |
| Inflammation | 8 (16%) | 10 (20%) | 15 (30%) | 10 (20%) |
| Mitotic Alteration | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| Mixed Cell Focus Pigmentation, Hemosiderin Regeneration Tension Lipidosis Bile Duct, Cyst Hepatocyte, Hypertrophy Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery Inflammation | 1 (2%) 7 (14%) 1 (2%) 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) 1 (2%) 6 (12%) 4 (8%) 1 (2%) 1 (2%) 1 (2%) (13) | 1 (2%) 1 (2%) 5 (10%) 1 (2%) 2 (4%) 5 (10%) | 1 (2%) 1 (2%) 8 (16%) 1 (2%) 1 (2%) 3 (6%) 3 (6%) 1 (2%) | |
|---|--|--|--|---|--|
| Pigmentation, Hemosiderin Regeneration Tension Lipidosis Bile Duct, Cyst Hepatocyte, Hypertrophy Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 7 (14%) 1 (2%) 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) 6 (12%) 4 (8%) 1 (2%) 1 (2%) | 1 (2%) 5 (10%) 1 (2%) 2 (4%) 5 (10%) | 1 (2%) 8 (16%) 1 (2%) 1 (2%) 3 (6%) 3 (6%) 1 (2%) | |
| Regeneration Tension Lipidosis Bile Duct, Cyst Hepatocyte, Hypertrophy Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 1 (2%) 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 6 (12%) 4 (8%) 1 (2%) 1 (2%) | 1 (2%) 5 (10%) 1 (2%) 2 (4%) 5 (10%) | 8 (16%) 1 (2%) 1 (2%) 3 (6%) 3 (6%) 1 (2%) | |
| Tension Lipidosis Bile Duct, Cyst Hepatocyte, Hypertrophy Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 1 (2%) 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 6 (12%) 4 (8%) 1 (2%) 1 (2%) | 5 (10%) 1 (2%) 2 (4%) 5 (10%) | 1 (2%) 1 (2%) 3 (6%) 3 (6%) 1 (2%) | |
| Bile Duct, Cyst Hepatocyte, Hypertrophy Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 1 (2%) 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 4 (8%) 1 (2%) 1 (2%) | 2 (4%) 5 (10%) | 1 (2%) 3 (6%) 3 (6%) 1 (2%) | |
| Hepatocyte, Hypertrophy Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) 1 (2%) 1 (2%) | 2 (4%) 5 (10%) | 1 (2%) 3 (6%) 3 (6%) 1 (2%) | |
| Hepatocyte, Mineralization Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 2 (4%) 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) 1 (2%) 1 (2%) | 5 (10%) | 3 (6%) 3 (6%) 1 (2%) | |
| Hepatocyte, Vacuolization Cytoplasmic Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 3 (6%) 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) 1 (2%) 1 (2%) | 5 (10%) | 3 (6%) 1 (2%) | |
| Hepatocyte, Vacuolization Cytoplasmic, Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) 1 (2%) | • , | 1 (2%) | |
| Diffuse Serosa, Fibrosis Serosa, Inflammation Mesentery | 1 (2%) 2 (4%) (16) 14 (88%) | 1 (2%) | • , | 1 (2%) | |
| Serosa, Fibrosis Serosa, Inflammation Mesentery | 2 (4%) (16) 14 (88%) | 1 (2%) (13) | (11) | | |
| Serosa, Inflammation Mesentery | 2 (4%) (16) 14 (88%) | 1 (2%) (13) | (11) | | |
| Mesentery | (16) 14 (88%) | 1 (2%) (13) | (11) | (12) | |
| | 14 (88%) | (13) | (11) | | |
| Inflammation | | | | (10) | |
| | | | 2 (18%) | 2 (20%) | |
| Necrosis | | 13 (100%) | 8 (73%) | 7 (70%) | |
| Pancreas | (50) | (50) | (50) | (50) | |
| Basophilic Focus | | | | 2 (4%) | |
| Inflammation | 1 (2%) | | | | |
| Acinus, Atrophy | | 2 (4%) | | - (1) | |
| Acinus, Hyperplasia | 6 (12%) | 3 (6%) | 7 (14%) | 9 (18%) | |
| Arteriole, Inflammation | | - 4 | | 1 (2%) | |
| Duct, Cyst | 1 (2%) | 2 (4%) | 4 (00) | | |
| Duct, Inflammation | (50) | (50) | 1 (2%) | (50) | |
| Salivary Glands | (50) | (50) | (50) | (50) | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) | |
| Inflammation | 2 (4%) | | | | |
| Ulcer | 1 (2%) | F (400() | 42 (20%) | F (400() | |
| Epithelium, Hyperplasia | 5 (10%) | 5 (10%) | 13 (26%) | 5 (10%) | |
| Stomach, Glandular | (50) | (50) | (50) | (50) | |
| Mineralization | | 2 (4%) | | 4 (20/) | |
| Epithelium, Cyst Epithelium, Hyperplasia | 2 (4%) | 1 (2%) | 1 (2%) | 1 (2%) | |
| Glands, Cyst | 2 (4%) | 1 (2%) | 1 (2%) | 3 (6%) | |
| Glands, Cyst Glands, Hyperplasia | | 2 (4%) | 1 (276) | 3 (0%) | |
| Tooth | (0) | (0) | (2) | (3) | |
| Dysplasia | (0) | (0) | (2) | 2 (67%) | |
| Inflammation | | | 1 (50%) | 2 (01 /0) | |
| Gingiva, Hyperplasia | | | 1 (3070) | 1 (33%) | |
| Peridontal Tissue, Fibrosis | | | | 2 (67%) | |
| Peridontal Tissue, Inflammation | | | | 1 (33%) | |
| . 55 | | | | . (5575) | |
| RDIOVASCULAR SYSTEM | | | | | |
| Blood Vessel | (50) | (50) | (50) | (50) | |

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) bis(2-Chloroethoxy)methane

Test Type: CHRONIC Route: SKIN APPLICATION Species/Strain: MICE/B6C3F1

TDMS No. 99028 - 06

CAS Number: 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG | |
|---|--|---|---|--|--|
| | | | | | |
| Aorta, Inflammation | | 1 (2%) | | | |
| Heart | (50) | (50) | (50) | (50) | |
| Artery, Inflammation | 1 (2%) | 3 (6%) | 2 (4%) | 1 (2%) | |
| Atrium, Thrombosis | | | 1 (2%) | 1 (2%) | |
| Epicardium, Inflammation | | | | 1 (2%) | |
| Myocardium, Cardiomyopathy | 10 (20%) | 7 (14%) | 10 (20%) | 17 (34%) | |
| Myocardium, Fibrosis | 1 (2%) | 1 (2%) | | 2 (4%) | |
| Myocardium, Infiltration Cellular, Mononuclear Cell | 9 (18%) | 7 (14%) | 10 (20%) | 17 (34%) | |
| Myocardium, Mineralization | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) | |
| Myocardium, Necrosis | 1 (2%) | , , | , , | , , | |
| Myocardium, Vacuolization Cytoplasmic | 14 (28%) | 4 (8%) | 6 (12%) | 13 (26%) | |
| Valve, Thrombosis | 1 (2%) | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) | |
| Angiectasis | (00) | (00) | (00) | 1 (2%) | |
| Atrophy | 1 (2%) | | | (' ' ' ' | |
| Allopity | | | | | |
| | | 11 (22%) | 7 (14%) | 11 (22%) | |
| Hyperplasia Hypertrophy | 11 (22%) 38 (76%) | 11 (22%) 46 (92%) | 7 (14%) 42 (84%) | 11 (22%) 40 (80%) | |
| Hyperplasia | 11 (22%) | 46 (92%) | | | |
| Hyperplasia Hypertrophy | 11 (22%) 38 (76%) | | 42 (84%) | 40 (80%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia | 11 (22%) 38 (76%) 50 (100%) | 46 (92%) 50 (100%) (50) | 42 (84%) 50 (100%) | 40 (80%) 48 (96%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla | 11 (22%) 38 (76%) 50 (100%) (50) | 46 (92%) 50 (100%) | 42 (84%) 50 (100%) (50) | 40 (80%) 48 (96%) (50) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) | 40 (80%) 48 (96%) (50) 2 (4%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) | 46 (92%) 50 (100%) (50) 2 (4%) (50) | 42`(84%') 50 (100%) (50) 7 (14%) (50) | 40 (80%) 48 (96%) (50) 2 (4%) (50) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) 2 (4%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) 1 (2%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) 3 (6%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hyperplasia | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) 1 (2%) 24 (48%) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) 2 (4%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) 1 (2%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) 1 (2%) 24 (48%) 1 (2%) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) 3 (6%) 27 (54%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia Thyroid Gland | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) 2 (4%) 24 (49%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) 1 (2%) 27 (54%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) 1 (2%) 24 (48%) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) 3 (6%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) 2 (4%) 24 (49%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) 1 (2%) 27 (54%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) 1 (2%) 24 (48%) 1 (2%) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) 3 (6%) 27 (54%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia Thyroid Gland Inflammation C-cell, Hyperplasia | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) 2 (4%) 24 (49%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) 1 (2%) 27 (54%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) 1 (2%) 24 (48%) 1 (2%) (50) 1 (2%) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) 3 (6%) 27 (54%) | |
| Hyperplasia Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Hyperplasia Pituitary Gland Pars Distalis, Angiectasis Pars Distalis, Cyst Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia Thyroid Gland Inflammation | 11 (22%) 38 (76%) 50 (100%) (50) 6 (12%) (50) 23 (46%) (49) 1 (2%) 2 (4%) 24 (49%) | 46 (92%) 50 (100%) (50) 2 (4%) (50) 23 (46%) (50) 2 (4%) 1 (2%) 27 (54%) | 42 (84%) 50 (100%) (50) 7 (14%) (50) 31 (62%) (50) 1 (2%) 24 (48%) 1 (2%) (50) | 40 (80%) 48 (96%) (50) 2 (4%) (50) 21 (42%) (50) 3 (6%) 27 (54%) | |

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|--|----------------|-----------|------------------|------------------|
| Clitaral Cland | (50) | (50) | (40) | (50) |
| Clitoral Gland | (50) | (50) | (49) | (50) |
| Inflammation | (50) | 1 (2%) | 1 (2%) | (50) |
| Ovary | (50) | (50) | (50) | (50) |
| Angiectasis | 12 (26%) | 1 (2%) | 7 (4.40/) | 15 (30%) |
| Cyst | 13 (26%) | 7 (14%) | 7 (14%) | |
| Hemorrhage | 2 (4%) | 1 (2%) | | 3 (6%) |
| Mineralization | 4 (00/) | 1 (2%) | | |
| Pigmentation, Hemosiderin | 1 (2%) | | | 4 (00() |
| Thrombosis Interstitial Cell, Hyperplasia | | | | 1 (2%) 1 (2%) |
| Periovarian Tissue, Inflammation | 2 (4%) | | | 1 (2%) |
| Uterus | 2 (4%) (50) | (50) | (50) | (50) |
| | (50) | (50) | (50) | 1 (2%) |
| Hemorrhage Endometrium, Hyperplasia, Cystic | 49 (98%) | 47 (94%) | 48 (96%) | 50 (100%) |
| Myometrium, Angiectasis | 1 (2%) | 47 (94%) | 46 (96%) | 50 (100%) |
| Myometrium, Cyst | 1 (276) | | | 1 (2%) |
| Vagina | (0) | (0) | (1) | (0) |
| MATOPOIETIC SYSTEM | | | | |
| Bone Marrow | (50) | (50) | (50) | (50) |
| Angiectasis | | | 1 (2%) | |
| Myelofibrosis | 8 (16%) | 3 (6%) | 8 (16%) | 11 (22%) |
| Lymph Node | (8) | (9) | (3) | (5) |
| Iliac, Degeneration, Cystic | 1 (13%) | | | |
| Iliac, Hemorrhage | 1 (13%) | | | |
| Lumbar, Hyperplasia, Lymphoid | 1 (13%) | | | |
| Pancreatic, Hyperplasia, Lymphoid | | 1 (11%) | | |
| Renal, Hyperplasia, Lymphoid | 1 (13%) | | | |
| Lymph Node, Mandibular | (50) | (50) | (50) | (49) |
| Infiltration Cellular, Plasma Cell | | | | 1 (2%) |
| Lymph Node, Mesenteric | (50) | (50) | (49) | (50) |
| Infiltration Cellular, Plasma Cell | | | 1 (2%) | |
| Necrosis | | . (50) | 1 (2%) | |
| Arteriole, Inflammation | (=0) | 1 (2%) | (==) | (==) |
| Spleen | (50) | (50) | (50) | (50) |
| Hematopoietic Cell Proliferation | 2 (4%) | 1 (2%) | 3 (6%) | 1 (2%) |
| Hyperplasia, Lymphoid | 1 (2%) | 4 (8%) | 0 (40() | 1 (2%) |
| Infiltration Cellular, Plasma Cell | 4 (00() | | 2 (4%) | |
| Capsule, Hyperplasia | 1 (2%) | (50) | (50) | (50) |
| Thymus | (50) | (50) | (50) | (50) |
| Atrophy | | | 1 (2%) 1 (2%) | 3 (6%) |
| Hyperplasia, Lymphoid | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

TDMS No. 99028 - 06

bis(2-Chloroethoxy)methane **CAS Number:** 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|--|--|--|--|--|
| INTEGUMENTARY SYSTEM | | | | |
| Mammary Gland Skin Site Of Application - Dermis, Fibrosis Site Of Application - Dermis, Inflammation Site Of Application - Epidermis, Hyperplasia Site Of Application - Epidermis, Ulcer | (48) (50) 4 (8%) 4 (8%) 3 (6%) 1 (2%) | (50) (50) 1 (2%) 2 (4%) 1 (2%) | (50) (50) 1 (2%) 3 (6%) 1 (2%) | (50) (50) 2 (4%) 1 (2%) 3 (6%) |
| MUSCULOSKELETAL SYSTEM | | | | |
| Bone | (50) | (50) | (50) | (50) |
| NERVOUS SYSTEM | | | | |
| Brain Spinal Cord Demyelination | (50) (2) 1 (50%) | (50) (0) | (50) (1) 1 (100%) | (50) (0) |
| RESPIRATORY SYSTEM | | | | |
| Lung Hemorrhage | (50) 1 (2%) | (50) | (50) | (50) |
| Infiltration Cellular Inflammation Alveolar Epithelium, Hyperplasia Alveolus, Infiltration Cellular, Histiocyte Arteriole, Inflammation | 1 (2%) 5 (10%) 1 (2%) | 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) | 4 (8%) | 1 (2%) 4 (8%) 2 (4%) |
| Serosa, Hyperplasia Nose Inflammation Polyp, Inflammatory | (50) 13 (26%) | (50) 8 (16%) | (50) 7 (14%) 1 (2%) | 1 (2%) (50) 6 (12%) |
| Glands, Olfactory Épithelium, Dilatation Glands, Respiratory Epithelium, Dilatation Respiratory Epithelium, Hyperplasia | 1 (2%) | 1 (2%) | 1 (2%) 1 (2%) | 2 (4%) |
| Septum, Cyst Pleura | (0) | (0) | 1 (2%) (1) | (0) |
| SPECIAL SENSES SYSTEM | | | | |
| Eye Cornea, Inflammation | (50) | (50) 2 (4%) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

bis(2-Chloroethoxy)methane CAS Number: 111-91-1

Date Report Requested: 04/07/2008 Time Report Requested: 11:52:50 First Dose M/F: 10/03/02 / 10/02/02

Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|---|------------------------------------|--------------------------|---------------------------|--------------------------|
| Retina, Dysplasia Harderian Gland Epithelium, Hyperplasia | (50) 12 (24%) | (50) 7 (14%) | 1 (2%) (50) 6 (12%) | 1 (2%) (50) 4 (8%) |
| JRINARY SYSTEM | | | | |
| Kidney Infarct Infiltration Cellular, Mononuclear Cell Inflammation | (50) 1 (2%) 4 (8%) 4 (8%) | (50) 1 (2%) 1 (2%) | (50) 3 (6%) 1 (2%) | (50) 3 (6%) 1 (2%) |
| Mineralization Nephropathy Capsule, Fibrosis | 9 (18%) 37 (74%) 1 (2%) | 8 (16%) 37 (74%) | 11 (22%) 42 (84%) | 9 (18%) 38 (76%) |
| Renal Tubule, Dilatation Renal Tubule, Pigmentation Urinary Bladder Amyloid Deposition | (50) | 1 (2%) 1 (2%) (50) | (50) | (50) 1 (2%) |
| Hyperplasia, Lymphoid Inflammation Inflammation, Chronic Arteriole, Inflammation | 1 (2%) | | 1 (2%) | 1 (2%) 1 (2%) |
| Arteriole, Muscularis, Degeneration | | 1 (2%) | | |

*** END OF REPORT ***

TDMS No. 99028 - 06 Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

a - Number of animals examined microscopically at site and number of animals with lesion